Immune Design is a late-stage immunotherapy company. Co. is focused on oncology and has designed its technologies to activate the immune system's ability to create tumor-specific cytotoxic T cells to fight cancer via distinct mechanisms. Co.'s primary product candidates are CMB305 and G100. CMB305 is a prime-boost cancer vaccine targeting the NY-ESO-1 tumor antigen, in which a prime called LV305 from Co.'s ZVex® platform is dosed sequentially with a boost from Co.'s GLAAS® platform. G100 activates both innate and adaptive immunity in the tumor microenvironment, including dendritic cells, to create an immune response against the tumor's set of antigens, including neoantigens.

IMDZ — News

IMDZ — Price Chart